Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/10854/3808

Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals
Massanella, Marta; Ouchi, Dan; Marfil, Sílvia; Llibre, Josep M.; Puertas, M.C.; Buzon, Maria J.; Richman, Douglas D.; Orna, Elisa; Stevenson, Mario; Gatell, J.M.; Domingo, Pere; Negredo, Eugenia; Martinez Picado, Francisco Javier; Clotet, Bonaventura; Blanco, Julià
Universitat de Vic - Universitat Central de Catalunya. Càtedra de la Sida i Malalties Relacionades
Abstract Background HIV-1 infection increases plasma levels of inflammatory markers. Combination antiretroviral therapy (cART) does not restore inflammatory markers to normal levels. Since intensification of cART with raltegravir reduced CD8 T-cell activation in the Discor-Ral and IntegRal studies, we have evaluated the effect of raltegravir intensification on several soluble inflammation markers in these studies. Methods Longitudinal plasma samples (0–48 weeks) from the IntegRal (n = 67, 22 control and 45 intensified individuals) and the Discor-Ral studies (44 individuals with CD4 T-cell counts<350 cells/µl, 14 control and 30 intensified) were assayed for 25 markers. Mann-Whitney, Wilcoxon, Spearman test and linear mixed models were used for analysis. Results At baseline, different inflammatory markers were strongly associated with HCV co-infection, lower CD4 counts and with cART regimens (being higher in PI-treated individuals), but poorly correlated with detection of markers of residual viral replication. Although raltegravir intensification reduced inflammation in individuals with lower CD4 T-cell counts, no effect of intensification was observed on plasma markers of inflammation in a global analysis. An association was found, however, between reductions in immune activation and plasma levels of the coagulation marker D-dimer, which exclusively decreased in intensified patients on protease inhibitor (PI)-based cART regimens (P = 0.040). Conclusions The inflammatory profile in treated HIV-infected individuals showed a complex association with HCV co-infection, the levels of CD4 T cells and the cART regimen. Raltegravir intensification specifically reduced D-dimer levels in PI-treated patients, highlighting the link between cART composition and residual viral replication; however, raltegravir had little effect on other inflammatory markers.
-Sida -- Tractament
Aquest document està subjecte a aquesta llicència Creative Commons
http://creativecommons.org/licenses/by/3.0/es/
Artículo
info:eu-repo/publishedVersion
Public Library of Science
         

Documentos con el texto completo de este documento

Ficheros Tamaño Formato Vista
artconlli_a2014 ... fferent_plasma_markers.pdf 927.9 KB application/pdf Vista/Abrir

Mostrar el registro completo del ítem

Documentos relacionados

Otros documentos del mismo autor/a